PDS Biotechnology Corpora... (PDSB)
PDS Biotechnology Statistics
Share Statistics
PDS Biotechnology has 45.4M shares outstanding. The number of shares has increased by 21.57% in one year.
| Shares Outstanding | 45.4M |
| Shares Change (YoY) | 21.57% |
| Shares Change (QoQ) | 19.19% |
| Owned by Institutions (%) | 11.52% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 300 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3M, so 6.74% of the outstanding shares have been sold short.
| Short Interest | 3M |
| Short % of Shares Out | 6.74% |
| Short % of Float | 6.93% |
| Short Ratio (days to cover) | 9.63 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -1.37 |
| PS Ratio | 0 |
| Forward PS | 15.8 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for PDS Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.64 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | -0.35 |
| Debt / FCF | -0.36 |
| Interest Coverage | 7.77 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,639,530,083.33 |
| Employee Count | 24 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 869.17M |
| Effective Tax Rate | -2.26% |
Stock Price Statistics
The stock price has increased by -64.61% in the last 52 weeks. The beta is 1.49, so PDS Biotechnology's price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | -64.61% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 2.29 |
| Relative Strength Index (RSI) | 58.22 |
| Average Volume (20 Days) | 639,454 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.32B |
| Net Income | -39.35B |
| EBITDA | -36.32B |
| EBIT | -43.15B |
| Earnings Per Share (EPS) | -1079.45 |
Balance Sheet
The company has 41.69B in cash and 12.62B in debt, giving a net cash position of 29.07B.
| Cash & Cash Equivalents | 41.69B |
| Total Debt | 12.62B |
| Net Cash | 29.07B |
| Retained Earnings | -182.11B |
| Total Assets | 45.36M |
| Working Capital | 27.97M |
Cash Flow
In the last 12 months, operating cash flow was -35.03B and capital expenditures 0, giving a free cash flow of -35.03B.
| Operating Cash Flow | -35.03B |
| Capital Expenditures | n/a |
| Free Cash Flow | -35.03B |
| FCF Per Share | -960.98 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PDSB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PDSB is $10, which is 657.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 657.6% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 18, 2019. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 18, 2019 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -6.07 |
| Piotroski F-Score | 2 |